Skip to main content

Table 4 Annual rate of exacerbations (95% confidence interval), per GOLD

From: Does the 2013 GOLD classification improve the ability to predict lung function decline, exacerbations and mortality: a post-hoc analysis of the 4-year UPLIFT trial

Old stage

P-value*

New stage

P-value*

Substage

P-value*

2

0.53 (0.50 - 0.55)

-

A

0.35 (0.29 - 0.41)

-

C1

0.47 (0.39 - 0.57)

-

3

0.72 (0.69 - 0.76)

<0.001

B

0.45 (0.42 - 0.48)

0.001

C2

0.55 (0.41-0.71)

0.37

4

0.80 (0.72 - 0.89)

0.09

C

0.58 (0.51 - 0.68)

0.001

C3

0.96 (0.70-1.24)

0.06

   

D

0.74 (0.71 - 0.77)

0.001

D1

0.56 (0.53-0.60)

-

      

D2

0.75 (0.69-0.81)

<0.001

      

D3

0.97 (0.92-1.04)

<0.001

AIC

22,697.09

  

22,571.27

  

22,417.35

 
  1. *Wald test of difference with category immediately above. Overall Wald test of equal rates across stages: p < 0.001 for all models. C1/D1: classified in C/D because of lung function impairment; C2/D2: in C/D because of exacerbation history; C3/D3: because of lung function and exacerbation history.
Back to article page

BMC Pulmonary Medicine

ISSN: 1471-2466

Contact us